Teva Pharmaceutical Industries Limited (TEVA)

Market Cap	24.10B
Revenue (ttm)	16.77B
Net Income (ttm)	-959.00M
Shares Out	1.13B
EPS (ttm)	-0.86
PE Ratio	n/a
Forward PE	8.05
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,191,945
Open	21.40
Previous Close	21.30
Day's Range	21.10 - 21.58
52-Week Range	10.75 - 22.80
Beta	0.73
Analysts	Buy
Price Target	21.00 (-1.13%)
Earnings Date	Jan 29, 2025

About TEVA

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1901
• Employees: 37,851
• Stock Exchange: NYSE
• Ticker Symbol: TEVA
• Website: https://www.tevapharm.com

Financial Performance

In 2023, Teva Pharmaceutical's revenue was $15.85 billion, an increase of 6.17% compared to the previous year's $14.93 billion. Losses were -$559.00 million, -77.15% less than in 2022.

Analyst Forecast

According to 7 analysts, the average rating for TEVA stock is "Buy." The 12-month stock price forecast is $21.0, which is a decrease of -1.13% from the latest price.

Price Target

$21.0

(-1.13% downside)

Analyst Consensus: Buy